In today’s session Horizon Pharma PLC (HZNP) recorded an unusually high (140) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the January, 2017 put, expecting serious HZNP decrease. With 140 contracts traded and 39794 open interest for the Jan, 17 contract, it seems this is a quite bearish bet. The option with symbol: HZNP170120P00015000 closed last at: $3.1 or 34.8% up. About 2.67M shares traded hands. Horizon Pharma PLC (NASDAQ:HZNP) has declined 12.70% since April 5, 2016 and is downtrending. It has underperformed by 14.66% the S&P500.
Horizon Pharma PLC (NASDAQ:HZNP) Ratings Coverage
Out of 9 analysts covering Horizon Pharma (NASDAQ:HZNP), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Horizon Pharma has been the topic of 19 analyst reports since September 9, 2015 according to StockzIntelligence Inc. Citigroup maintained the shares of HZNP in a report on Tuesday, August 9 with “Neutral” rating. The rating was maintained by Mizuho on Monday, December 14 with “Buy”. The rating was initiated by Goldman Sachs with “Buy” on Thursday, December 17. The rating was maintained by Mizuho on Tuesday, May 3 with “Buy”. Mizuho maintained Horizon Pharma PLC (NASDAQ:HZNP) rating on Monday, October 31. Mizuho has “Buy” rating and $29 price target. Mizuho maintained Horizon Pharma PLC (NASDAQ:HZNP) rating on Tuesday, November 10. Mizuho has “Buy” rating and $34 price target. The firm has “Buy” rating by Mizuho given on Tuesday, May 10. The stock of Horizon Pharma PLC (NASDAQ:HZNP) has “Mkt Outperform” rating given on Wednesday, September 9 by JMP Securities. The rating was downgraded by Cowen & Co on Friday, September 16 to “Market Perform”. The company was maintained on Tuesday, September 13 by Mizuho.
According to Zacks Investment Research, “Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company’s U.S. marketed products are ACTIMMUNEÂ® (interferon gamma-1b), DUEXISÂ® (ibuprofen/famotidine), PENNSAIDÂ® (diclofenac sodium topical solution) 2% w/w, RAYOSÂ® (prednisone) delayed-release tablets and VIMOVOÂ® (naproxen/esomeprazole magnesium). Horizon’s global headquarters are in Dublin, Ireland.”
Insitutional Activity: The institutional sentiment increased to 1.21 in Q2 2016. Its up 0.21, from 1 in 2016Q1. The ratio increased, as 46 funds sold all Horizon Pharma PLC shares owned while 45 reduced positions. 38 funds bought stakes while 72 increased positions. They now own 135.34 million shares or 2.87% less from 139.33 million shares in 2016Q1.
1St Global Advisors Incorporated accumulated 13,116 shares or 0.03% of the stock. Qs Investors Lc accumulated 84,446 shares or 0.01% of the stock. Invesco Ltd holds 0% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP) for 42,651 shares. Millennium Mngmt Lc holds 150,675 shares or 0.01% of its portfolio. Blackrock, a New York-based fund reported 22,344 shares. State Street has 0.01% invested in the company for 4.20M shares. Gilder Gagnon Howe And Communications Ltd Llc has 0% invested in the company for 4,709 shares. Diam Com Ltd owns 403,067 shares or 0.1% of their US portfolio. Envestnet Asset Management holds 0.01% or 120,329 shares in its portfolio. Spot Trading Limited Company last reported 0.01% of its portfolio in the stock. Moreover, Carlson L P has 0.05% invested in Horizon Pharma PLC (NASDAQ:HZNP) for 221,000 shares. Redwood Invs Llc holds 254,046 shares or 0.38% of its portfolio. Us Financial Bank De last reported 2,570 shares in the company. Highbridge Capital Limited Liability Com has 0.21% invested in the company for 777,471 shares. Lpl Finance Ltd reported 20,992 shares or 0% of all its holdings.
Insider Transactions: Since June 15, 2016, the stock had 0 buys, and 2 sales for $500,280 net activity. Nohria Virinder also sold $442,280 worth of Horizon Pharma PLC (NASDAQ:HZNP) on Wednesday, June 15. SHERMAN JEFFREY W sold $58,000 worth of Horizon Pharma PLC (NASDAQ:HZNP) on Tuesday, August 2.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The company has a market cap of $3.13 billion. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It currently has negative earnings. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
HZNP Company Profile
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, incorporated on December 20, 2011, is a biopharmaceutical company. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. The Firm markets approximately nine medicines through its orphan, primary care and rheumatology business units. The Company’s segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. The Company’s marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Firm also developed DUEXIS and RAYOS, known as LODOTRA.
More important recent Horizon Pharma PLC (NASDAQ:HZNP) news were published by: Investorplace.com which released: “Dump Horizon Pharma PLC (HZNP) Stock Now! Don’t Wait!” on October 11, 2016, also Nasdaq.com published article titled: “Horizon Pharma plc Completes Acquisition of Raptor Pharmaceutical Corp.”, Globenewswire.com published: “Horizon Pharma plc Announces Availability of RAVICTI® (glycerol phenylbutyrate …” on November 03, 2016. More interesting news about Horizon Pharma PLC (NASDAQ:HZNP) was released by: Globenewswire.com and their article: “Horizon Pharma plc Announces Pricing of Private Offering of Senior Notes” with publication date: October 20, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.